Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text Volltext
DOI
PMC
 |
Open Access Gold |
as soon as is submitted to ZB.
Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity.
OncoImmunology 2:e22410 (2013)
The clinical use of lymphocytes engineered to express high affinity T-cell receptors (TCRs) specific for two broadly expressed tumor-associated antigens is strongly limited by MHC-restricted fratricide of lymphocytes and TCR-mediated killing of hematopoietic stem cells. Specific clinical applications must therefore be conceived to bypass these limitations.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
0.000
0.000
4
4
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Hematopoietic Stem Cell Toxicity ; Hyluronan-mediated Motility Receptor ; Mhc-restricted Fratricide ; Survivin ; Tcr Gene Therapy; T-cells ; Dendritic Cells ; Antigens
Language
english
Publication Year
2013
HGF-reported in Year
2013
ISSN (print) / ISBN
2162-4011
e-ISSN
2162-402X
Journal
OncoImmunology
Quellenangaben
Volume: 2,
Issue: 1,
Article Number: e22410
Publisher
Taylor & Francis
Publishing Place
Philadelphia
Reviewing status
Peer reviewed
Institute(s)
Institute of Molecular Immunology (IMI)
POF-Topic(s)
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Research field(s)
Immune Response and Infection
PSP Element(s)
G-501700-001
G-501790-001
G-501790-001
PubMed ID
23483031
WOS ID
WOS:000317262600028
Scopus ID
84886944178
Erfassungsdatum
2013-05-09